Using data from the PROVE-HF study, investigators conducted a subanalysis of outcomes among patients receiving sacubitril/valsartan who did and did not have ischemic heart disease.
TRILUMINATE, the first pivotal trial of a device for repair of severe tricuspid regurgitation, showed a large reduction in valve dysfunction associated with substantial improvement in quality of life.
Presentations highlight the significant potential clinical benefits of managing congestion in patients with heart failure with FUROSCIX (furosemide injection) at home